Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine.
Takafumi MieTakashi SasakiTakeshi OkamotoTakaaki FurukawaTsuyoshi TakedaAkiyoshi KasugaMasato OzakaNaoki SasahiraPublished in: Cancers (2024)
First-line chemotherapy has been established for advanced biliary tract cancer (BTC). However, few treatment options are available as second-line treatment. Advances in comprehensive genomic analysis revealed that nearly half of patients with BTC harbor targetable genetic alterations such as fibroblast growth factor receptor (FGFR), isocitrate dehydrogenase (IDH), BRAF, human epidermal growth factor receptor 2 (HER2), microsatellite instability (MSI)-high, neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), and poly (adenosine diphosphate-ribose) polymerase (PARP). This review summarizes currently available options in precision medicine and clinical trials for patients with advanced BTC.
Keyphrases
- epidermal growth factor receptor
- papillary thyroid
- clinical trial
- tyrosine kinase
- current status
- squamous cell
- endothelial cells
- advanced non small cell lung cancer
- wild type
- dna damage
- childhood cancer
- gene expression
- dna repair
- genome wide
- squamous cell carcinoma
- oxidative stress
- binding protein
- copy number
- pluripotent stem cells
- combination therapy
- rectal cancer
- high grade
- structural basis